Clinical Trials Logo

Pelvic Inflammatory Disease clinical trials

View clinical trials related to Pelvic Inflammatory Disease.

Filter by:

NCT ID: NCT02567812 Recruiting - Clinical trials for Inflammatory Pelvic Disease

Database of Pelvic Inflammatory Disease

Start date: October 2015
Phase:
Study type: Observational [Patient Registry]

The aim of this prospective study is to collect data on in-patients with pelvic inflammatory disease(PID) at Kangbuk Samsung Hospital.

NCT ID: NCT01842100 Completed - Clinical trials for Sexually Transmitted Infections

To Compare the Strategies of Universal Antibiotic Prophylaxis Versus Screen-and-treat in Reducing Infective Complications and Re-infection in Women Who Undergo Termination of Pregnancy

Start date: September 1999
Phase: N/A
Study type: Interventional

Screen-and-treat approach reduces postabortal pelvic inflammatory disease after induced abortion, and at the same time alters women's sexual behavior and prevents further re-infection by sexually transmitted infections when compared to the universal antibiotic prophylaxis strategy.

NCT ID: NCT01799356 Completed - Clinical trials for Pelvic Inflammatory Disease

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

Start date: June 2010
Phase: Phase 4
Study type: Interventional

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

NCT ID: NCT01793584 Completed - Endometriosis Clinical Trials

Surgical Success After Laparoscopic vs Abdominal Hysterectomy

Start date: February 2013
Phase: N/A
Study type: Interventional

The purpose of the proposed pilot study is to investigate the effectiveness, cost, safety, and long-term impact on quality of life of laparoscopic hysterectomy (LH) in relation to abdominal hysterectomy (AH) for the treatment of benign gynecologic disease in women through a randomized surgical trial.

NCT ID: NCT01671280 Completed - Clinical trials for Community-acquired Pneumonia

Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan)

RESCUE
Start date: September 2012
Phase: N/A
Study type: Observational

To collect the efficacy and safety information of Azithromycin IV related to their appropriate use in daily practice

NCT ID: NCT01640379 Completed - Clinical trials for Pelvic Inflammatory Disease (PID)

Technology Enhanced Community Health Nursing (TECH-N) Study

TECH-N
Start date: July 2012
Phase: N/A
Study type: Interventional

The investigators are enrolling 350 young women 13-25 years old diagnosed with pelvic inflammatory disease (PID) in Baltimore and randomize them to receive community health nurse (CHN) clinical support using a single post-PID face-to-face clinical evaluation and short messaging system communication support during the 30. The investigators hypothesize that repackaging the recommended Centers for Disease Control and Prevention (CDC) follow-up visit using a technology-enhanced community health nursing intervention (TECH-N) with integration of an evidence-based sexually transmitted infection (STI) prevention curriculum will reduce rates of short-term repeat infection by improving adherence to PID treatment and reducing unprotected intercourse and be more cost-effective compared with outpatient standard of care (and hospitalization).

NCT ID: NCT01299259 Completed - Clinical trials for Pelvic Inflammatory Disease

Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease

Start date: February 2011
Phase: N/A
Study type: Interventional

The investigators hypothesize that text message reminders to girls diagnosed with pelvic inflammatory disease (PID) in the emergency department (ED) will improve follow-up to their primary care provider (PCP) after being discharged from the ED.

NCT ID: NCT01241110 Completed - Clinical trials for Pelvic Inflammatory Disease

To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment

CTO
Start date: January 2010
Phase: Phase 4
Study type: Interventional

Objective: To compare two oral treatments: Ofloxacin + Metronidazole, and Azitromycin +Metronidazole in outpatients with Pelvic Inflammatory Disease. Materials and Methods: Two hundred patients divided to two groups( A , B). Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy

NCT ID: NCT01236131 Completed - Clinical trials for Pelvic Inflammatory Disease

The Role of Novel Organisms in Acute Endometritis

Start date: November 2010
Phase: N/A
Study type: Observational

The goal of this project is to identify the microorganisms present in the endometrial samples obtained from women with or without evidence of endometritis using a combination of culture methods, rRNA sequencing and whole genomic sequencing. The overarching aim of these studies is to identify the etiology of endometritis. The investigators will define the role of fastidious anaerobic microorganisms in the etiology of PID, and assess whether antibiotic treatment regimens used for the treatment of PID have activity against the novel organisms linked with pelvic infections.

NCT ID: NCT01160640 Completed - Clinical trials for Pelvic Inflammatory Disease

The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This study is a randomized placebo-controlled trial comparing two antibiotic treatment regimens for acute PID. Women with acute PID will be randomized to one of two treatment regimens: 1) a single intramuscular dose of ceftriaxone 250 mg, doxycycline 100 mg orally twice a day for 14 days, along with placebo tablets orally twice a day for 14 days or 2) same doses of ceftriaxone and doxycycline, and metronidazole 500 mg orally twice a day for 14 days. The primary objective is to compare the eradication of anaerobic organisms from the upper genital tract between women who receive standard outpatient antibiotic treatment to those who receive standard outpatient treatment along with a two-week course of metronidazole.